GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    An assessment of the risk, cost‐effectiveness, and perceived benefits of anti‐parvovirus B19 tested blood products
    Wiley ; 2019
    In:  Transfusion Vol. 59, No. 7 ( 2019-07), p. 2352-2360
    Details
    In: Transfusion, Wiley, Vol. 59, No. 7 ( 2019-07), p. 2352-2360
    Abstract: Parvovirus B19 (B19V) can cause severe anemia, hydrops foetalis, and even death in vulnerable patients. To prevent transfusion‐transmitted B19V infection of at‐risk patients, B19V antibody screening of blood donors was implemented. The cost‐effectiveness of this intervention is unclear, as the likelihood of transmission through blood and subsequent complications for recipients are unknown. This study estimates the cost‐effectiveness of anti‐B19V donor screening in the Netherlands. STUDY DESIGN AND METHODS The estimates needed for the cost‐effectiveness model were: the occurrence of B19V in Dutch blood donors, the number of anti‐B19V tested products required by hospitals, the likelihood of morbidity and mortality given B19V infection, treatment costs, and screening costs. These estimates were obtained from literature and observational data. When data were unavailable, structured expert judgment elicitation and statistical modeling were applied. RESULTS The costs of preventing one transfusion transmitted B19V infection are estimated at €68,942 (€42,045 – €102,080). On average, 1.25 cases of morbidity and 0.12 cases of mortality are prevented annually. Although the perceived risk of transfusion transmitted B19V infection was low, half of the treating physicians favored anti‐B19V screening. CONCLUSION The estimated mortality and morbidity caused by B19V infection was low in the risk groups. The cost‐effectiveness ratio is similar to other blood safety screening measures. No guidance exists to evaluate the acceptability of this ratio. The explicit overview of costs and effects may further guide the discussion of the desirability of B19V safe blood products.
    Type of Medium: Online Resource
    ISSN: 0041-1132 , 1537-2995
    URL: Issue
    URL: Article
    DOI: 10.1111/trf.2019.59.issue-7
    DOI: 10.1111/trf.15324
    Language: English
    Publisher: Wiley
    Publication Date: 2019
    detail.hit.zdb_id: 2018415-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Effect on the quality of blood components after simulated blood transfusions using volumetric infusion pumps : EVALUATION OF VOLUMETRIC INFUSION PUMPS
    Wiley ; 2011
    In:  Transfusion Vol. 51, No. 8 ( 2011-08), p. 1835-1839
    Details
    In: Transfusion, Wiley, Vol. 51, No. 8 ( 2011-08), p. 1835-1839
    Type of Medium: Online Resource
    ISSN: 0041-1132
    URL: Issue
    URL: Article
    DOI: 10.1111/trf.2011.51.issue-8
    DOI: 10.1111/j.1537-2995.2010.03037.x
    Language: English
    Publisher: Wiley
    Publication Date: 2011
    detail.hit.zdb_id: 2018415-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    West Nile virus and blood transfusion safety: A European perspective
    Wiley ; 2021
    In:  Vox Sanguinis Vol. 116, No. 10 ( 2021-11), p. 1094-1101
    Details
    In: Vox Sanguinis, Wiley, Vol. 116, No. 10 ( 2021-11), p. 1094-1101
    Abstract: There is a growing concern for the transmission of arboviral infections by blood transfusion in Europe. However, no assessment of the risk of transmission through all European blood supplies has been reported. Risk regulations at a European level should take differences in local transmission risk and the risk of transmission by travelling donors into consideration. Materials and Methods A risk model and publicly available tool were developed to calculate the risk of transmission by all European blood supplies for arboviral outbreaks within Europe. Data on individual European blood supplies from Council of Europe reports and inter‐European travel data from EUROSTAT were used to populate this model. Results Each neuroinvasive case of WNV reported in Europe will on average result in 0·43 (95%CI: 0·32–0·55) infected blood product by locally infected donors and 0·010 (95%CI: 0·006–0·015) infected products by travelling donors. On basis of the 1373 neuroinvasive human WNV cases reported in the outbreak of 2018, it is estimated that without safety interventions this outbreak would have resulted in 708 (95%CI: 523–922) infected components derived from resident donors. Noncompliance to European regulations, which requires donor deferral or testing of donors who visited WNV‐infected areas, would have resulted in 7.4 (95%CI: 4·7–11·1) infected blood components derived from infectious travelling donors exposed in outbreak areas throughout Europe. Conclusion The risk of WNV transmission by a local outbreak is on average 113 times (95%CI: 95–139), so two orders of magnitude higher than the risk of transmission by travelling donors in Europe.
    Type of Medium: Online Resource
    ISSN: 0042-9007 , 1423-0410
    URL: Issue
    URL: Article
    DOI: 10.1111/vox.v116.10
    DOI: 10.1111/vox.13112
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 1483587-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Rare transmission of hepatitis B virus by D utch donors with occult infection
    Wiley ; 2016
    In:  Transfusion Vol. 56, No. 3 ( 2016-03), p. 691-698
    Details
    In: Transfusion, Wiley, Vol. 56, No. 3 ( 2016-03), p. 691-698
    Abstract: To reduce the rate of transfusion‐transmitted hepatitis B virus (HBV), HBV DNA testing was introduced for all Dutch blood donations in 2008, in addition to the existing screening for HBV surface antigen (HBsAg). This study describes the lookback results for repeat donors with an “HBV DNA‐only” test result (HBV DNA‐positive and HBsAg‐negative). STUDY DESIGN AND METHODS From November 2008 until June 2011, a total of 2.3 million blood donations were tested for HBV DNA and 22 donors showed the HBV DNA‐only profile. Four donors had early preseroconversion HBV infection, two showed suppressed infection after vaccination, and 16 donors had occult chronic HBV infection (OBI). Potentially infectious donations were traced back as far as 1992. If possible the recipients were tested for current and past HBV infection. RESULTS A total of 416 implicated donations could be traced in blood bank records, involving 448 issued blood products. For 170 (38%) of the recipients no information was obtained from the hospitals; 196 (44%) recipients had died, and 82 (18%) were tested for HBV. Six recipients tested positive for current (n = 4) or past (n = 2) HBV infection. For two recipients transfusion was ruled out as the source of infection. Three patients showed HBV DNA sequences matching with the HBV in one common OBI donor. Overall, in four of 82 tested recipients (5%) HBV transmission was likely. CONCLUSION In our lookback study HBV testing was possible in only a minority (18%) of potentially exposed recipients. A low transmission rate (5%) was observed in recipients of blood components from donors with OBI.
    Type of Medium: Online Resource
    ISSN: 0041-1132 , 1537-2995
    URL: Issue
    URL: Article
    DOI: 10.1111/trf.2016.56.issue-3
    DOI: 10.1111/trf.13401
    Language: English
    Publisher: Wiley
    Publication Date: 2016
    detail.hit.zdb_id: 2018415-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Predonation screening of candidate donors and prevention of window period donations
    Wiley ; 2015
    In:  Transfusion Vol. 55, No. 2 ( 2015-02), p. 373-378
    Details
    In: Transfusion, Wiley, Vol. 55, No. 2 ( 2015-02), p. 373-378
    Abstract: Infectious window period donations slip through routine donor screening procedures. To explore the potential value of predonation screening of candidate donors, we compared the proportion of incident transfusion‐transmissible infections in candidate donors, in first‐time donors, and in repeat donors. Study Design and Methods A retrospective analysis was performed of all incident hepatitis B virus ( HBV ), hepatitis C virus ( HCV ), and human immunodeficiency virus ( HIV ) infections in candidate, first‐time, and repeat donors in the N etherlands during the period 2009 to 2013. Results In total, 176,716 candidate donors, 144,226 first‐time donations, and 4,143,455 repeat donations were screened for HBV , HCV , and HIV infection. Acute HBV infection was identified in the predonation sample of six candidate donors. One first‐time donor, testing HIV ‐negative at predonation screening, tested positive for anti‐ HIV and HIV RNA in the first donation 29 days later. Among repeat donations we identified 15, one, and six incident HBV , HCV and HIV infections, respectively. The proportion of incident infections among candidate donors/first‐time donations/repeat donations was for HBV , 3.40/0/0.36; for HCV , 0/0/0.02; and for HIV 0/0.69/0.14 per 100,000, respectively. Conclusion Predonation screening of candidate donors very likely causes a loss of donations, but it might prevent undetected window period donations. Further studies are necessary to determine the value of predonation screening as an additional safety measure.
    Type of Medium: Online Resource
    ISSN: 0041-1132 , 1537-2995
    URL: Issue
    URL: Article
    DOI: 10.1111/trf.v55.2
    DOI: 10.1111/trf.12809
    Language: English
    Publisher: Wiley
    Publication Date: 2015
    detail.hit.zdb_id: 2018415-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Climate change and parasitic risk to the blood supply
    Wiley ; 2023
    In:  Transfusion Vol. 63, No. 3 ( 2023-03), p. 638-645
    Details
    In: Transfusion, Wiley, Vol. 63, No. 3 ( 2023-03), p. 638-645
    Type of Medium: Online Resource
    ISSN: 0041-1132 , 1537-2995
    URL: Issue
    URL: Article
    DOI: 10.1111/trf.v63.3
    DOI: 10.1111/trf.17234
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2018415-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Research initiatives of blood services worldwide in response to the covid‐19 pandemic
    Wiley ; 2021
    In:  Vox Sanguinis Vol. 116, No. 3 ( 2021-03), p. 296-304
    Details
    In: Vox Sanguinis, Wiley, Vol. 116, No. 3 ( 2021-03), p. 296-304
    Abstract: While coronavirus (COVID‐19) is not transfusion‐transmitted, the impact of the global pandemic on blood services worldwide is complex. Convalescent plasma may offer treatment, but efficacy and safety are not established. Measuring seroprevalence in donors would inform public health policy. Here, we survey blood services around the world to assess the different research programmes related to COVID‐19 planned or in progress. Materials and Methods Blood collection services were surveyed in June 2020 to determine whether they were participating in serosurveys or convalescent plasma collection and clinical trials. Results A total of 48 countries (77% of those contacted) responded. Seroprevalence studies are planned or in progress in 73% of countries surveyed and in all continents, including low‐ and middle‐income countries. Most aimed to inform public health policy. Convalescent plasma programmes have been initiated around the globe (79% of surveyed), about three quarters as clinical trials in high‐, middle‐ and low‐income countries. Conclusion Blood services around the world have drawn upon their operational capacity to provide much‐needed seroprevalence data to inform public health. They have rapidly implemented preparation of potential treatment when few treatments are available and mostly as clinical trials. At the same time, they must continue to provide blood products for recipients despite challenges of working in a state of emergency. It is important to track and coordinate research efforts across jurisdictions to gain a composite evidence‐based view that will influence future practice and preparative strategies.
    Type of Medium: Online Resource
    ISSN: 0042-9007 , 1423-0410
    URL: Issue
    URL: Article
    DOI: 10.1111/vox.v116.3
    DOI: 10.1111/vox.12995
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 1483587-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Travel behavior and deferral of D utch blood donors: consequences for donor availability
    Wiley ; 2015
    In:  Transfusion Vol. 55, No. 1 ( 2015-01), p. 79-85
    Details
    In: Transfusion, Wiley, Vol. 55, No. 1 ( 2015-01), p. 79-85
    Abstract: Donors returning from areas with outbreaks of infectious diseases may donate infectious blood back home. Geographic donor deferral is an effective measure to ensure the blood safety, but donor deferral may pose a threat for the blood supply especially after holiday seasons. Insight into the travel behavior of blood donors is a first step to define appropriate deferral strategies. This study describes the travel behavior of D utch donors, the actual deferral, and the consequences of deferral strategies on donor availability. Study Design and Methods A questionnaire designed to assess travel behavior (destination, frequency, and duration of travels) was sent to 2000 D utch donors. The impact of travel deferral policies on donor availability was calculated, expressed as proportionate decrease in donor availability. The deferral policies considered were 1) deferral based on entire countries instead of affected regions where an infection is prevalent and 2) deferral after any travel outside E urope (“universal deferral”). Results Of the 1340 respondents, 790 (58.9%) donors traveled within E urope only, 61 (4.6%) outside E urope only, and 250 (18.7%) within and outside E urope. The deferral for entire countries and universal deferral would lead to 11.1 and 11.4% decrease in donor availability, respectively. Conclusion Most D utch donors traveled outside the N etherlands, while 23.2% traveled outside E urope. Universal deferral resulted in an additional decrease in donor availability of 0.3% compared with deferral for entire countries instead of affected regions where an infection is prevalent. Thus, the universal deferral could be considered as a simpler and safer measure.
    Type of Medium: Online Resource
    ISSN: 0041-1132 , 1537-2995
    URL: Issue
    URL: Article
    DOI: 10.1111/trf.2015.55.issue-1
    DOI: 10.1111/trf.12783
    Language: English
    Publisher: Wiley
    Publication Date: 2015
    detail.hit.zdb_id: 2018415-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...